Target Research Articles

  1. Target Transcription Factor States, Not Pockets 8/21/2026

    Transcription factors expose broad protein–DNA and protein–protein interfaces, contain intrinsically disordered regions, and exchange partners as cellular context changes.

  2. Beyond Apoptosis: Context Is The Target 8/17/2026

    Cells that evade apoptosis do not necessarily evade death; they may remain vulnerable to ferroptosis, pyroptosis, necroptosis, or another regulated cell death program.

  3. Alpha-Synuclein Is Not One Target 8/14/2026

    Alpha-synuclein is not one target, and a nanobody is not a smaller antibody with automatic access.

  4. Drug Discovery AI Has A Ground Truth Problem 7/27/2026

    If the goal is more healthy years of life, the bottlenecks are target identification, target validation, and clinical testing. Why is AI not transforming those steps? Because the data are not there.

  5. Wondering If Your Org Should Purchase R&D Datasets? 7/1/2026

    Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.

  6. The Future Is Ancient: Evolution, Metabolics, And AI 6/23/2026

    We caught up with Hannah Gordon, Ph.D., chief scientific officer of Enveda, to discuss why the future may depend more on decoding nature’s evolutionarily selected chemistry.

  7. Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire 6/19/2026

    We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.

  8. How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3) 6/15/2026

    Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.

  9. 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics 6/11/2026

    Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.

  10. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

    Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.